VJHemOnc Podcast by VJHemOnc

What's VJHemOnc Podcast about?

The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com

What's VJHemOnc Podcast about?

Download our free app to listen on your phone

VJHemOnc Podcast episodes:

Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks

BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients

The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies

iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials

Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs

Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome

The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs

Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification

CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors

Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception

The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT

Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology

Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy

Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks

Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents

Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023

Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine

Updates, challenges and novel agents being explored in BPDCN

Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets

Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy

ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis

MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF

iwNHL 2023 Session V: Expanding the CAR platform in NHL

iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials

iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies

Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP

iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL

MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches

iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma

iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma

iwAL 2023 Session IV: Transplantation and immunotherapies in AML: improving patient outcomes

Classifying frailty and approaching elderly patients with lymphoma

Updates on the diagnosis, risk stratification and treatment of lower-risk MDS

iwAL 2023 Session III: The relevance of TP53 mutation in AML

iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more

iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics

Applications of MRD in multiple myeloma: using MRD to guide treatment decisions

The importance of addressing racial disparities & differences in survival in patients with acute leukemias

Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL

Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions

Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored

Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma

Overcoming barriers to CAR-T therapy: improving access and cost

The importance of addressing quality of life and improving symptom management in MPNs

Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team

Hemophilia: the current standard of care and the value of novel gene therapies

CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors

Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice

Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management

iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials